Leerink Partnrs restated their outperform rating on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report report published on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q4 2023 earnings at ($0.73) EPS and FY2024 earnings at ($2.13) EPS. Several other equities research analysts also recently weighed in […]
Stifel Nicolaus began coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $20.00 target price on the stock. LXEO has been the subject of a number of other research reports. Royal Bank of Canada assumed coverage […]
SVB Leerink began coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. The firm issued an outperform rating and a $19.00 price objective on the stock. Separately, Chardan Capital started coverage on Lexeo Therapeutics in a report on Tuesday. They set a buy rating […]
Chardan Capital initiated coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a report issued on Tuesday, MarketBeat reports. The firm issued a buy rating and a $23.00 price objective on the stock. Chardan Capital also issued estimates for Lexeo Therapeutics’ FY2023 earnings at ($3.30) EPS and FY2024 earnings at ($2.74) EPS. Lexeo […]
SVB Leerink started coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report released on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $19.00 price target on the stock. Separately, Chardan Capital began coverage on Lexeo Therapeutics in a research report on Tuesday. They issued a buy rating […]